Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray
Dylan Chou, Hsien‐Yu Peng, Tzer-Bin Lin, et al.
Neuropharmacology (2018) Vol. 139, pp. 1-12
Closed Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
Kenji Hashimoto
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 10, pp. 613-627
Open Access | Times Cited: 286
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei Yan, Lijia Chang, Kenji Hashimoto
Molecular Psychiatry (2021) Vol. 27, Iss. 1, pp. 559-573
Open Access | Times Cited: 180
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 161
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 116
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Kyle A. Brown, Todd D. Gould
Molecular Psychiatry (2024) Vol. 29, Iss. 4, pp. 1114-1127
Open Access | Times Cited: 16
Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function
Eric W. Lumsden, Timothy A. Troppoli, Scott J. Myers, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 11, pp. 5160-5169
Open Access | Times Cited: 133
( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 13, pp. 6441-6450
Open Access | Times Cited: 128
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Todd D. Gould, Carlos A. Zarate, Scott M. Thompson
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 213-236
Open Access | Times Cited: 117
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Jaclyn N. Highland, Panos Zanos, Lace M. Riggs, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 2, pp. 763-791
Open Access | Times Cited: 75
Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Songbai Xu, Xiaoxiao Yao, Bingjin Li, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 38
The role of neurotrophic factors in novel, rapid psychiatric treatments
Jihye Kim, Michelle He, Alina K. Widmann, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 227-245
Closed Access | Times Cited: 24
(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses
Panos Zanos, Jaclyn N. Highland, Xin Liu, et al.
British Journal of Pharmacology (2019) Vol. 176, Iss. 14, pp. 2573-2592
Open Access | Times Cited: 75
(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism
Yukio Ago, Wataru Tanabe, Momoko Higuchi, et al.
The International Journal of Neuropsychopharmacology (2019) Vol. 22, Iss. 10, pp. 665-674
Open Access | Times Cited: 73
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Cristan Farmer, Jessica R. Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1398-1404
Open Access | Times Cited: 69
The cerebellum under stress
Josep M. Montero Moreno
Frontiers in Neuroendocrinology (2019) Vol. 54, pp. 100774-100774
Closed Access | Times Cited: 58
An update on NMDA antagonists in depression
Bartłomiej Pochwat, Gabriel Nowak, Bernadeta Szewczyk
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 11, pp. 1055-1067
Closed Access | Times Cited: 54
Neurobiology of Depression: Chronic Stress Alters the Glutamatergic System in the Brain—Focusing on AMPA Receptor
Ming Tatt Lee, Wei‐Hao Peng, Hung‐Wei Kan, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1005-1005
Open Access | Times Cited: 33
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Jordi Bonaventura, Juan L. Gomez, Meghan L. Carlton, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 10, pp. 4144-4156
Open Access | Times Cited: 31
Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants
Yating Wang, Ningning Zhang, Lingjie Liu, et al.
Biochemical and Biophysical Research Communications (2022) Vol. 594, pp. 46-56
Closed Access | Times Cited: 30
Exploring the multifaceted potential of (R)-ketamine beyond antidepressant applications
Senbing Zhang, Yanzhu Pu, Jianning Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
Shruti M. Raja, Jeffrey T. Guptill, Michelle Mack, et al.
Clinical Pharmacology & Therapeutics (2024)
Open Access | Times Cited: 6
Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine
Jaclyn N. Highland, Patrick J. Morris, Panos Zanos, et al.
Journal of Psychopharmacology (2018) Vol. 33, Iss. 1, pp. 12-24
Open Access | Times Cited: 50
(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism
Lace M. Riggs, Yasco Aracava, Panos Zanos, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 2, pp. 426-436
Open Access | Times Cited: 47
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Andrew J. Polis, Paul J. Fitzgerald, Pho J. Hale, et al.
Behavioural Brain Research (2019) Vol. 376, pp. 112153-112153
Open Access | Times Cited: 45
Depression and antidepressant effects of ketamine and its metabolites: The pivotal role of gut microbiota
Hao Hua, Chaoli Huang, Hanyu Liu, et al.
Neuropharmacology (2022) Vol. 220, pp. 109272-109272
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top